Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 1;50(6):47-52.
doi: 10.15586/aei.v50i6.495. eCollection 2022.

Omalizumab and allergen immunotherapy for respiratory allergies: A mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

Maria De Filippo  1   2 , Martina Votto  1   3 , Lucia Caminiti  4 , Francesco Carella  5 , Giovanna De Castro  6 , Massimo Landi  7 , Roberta Olcese  8 , Ilenia Panasiti  4 , Mario Vernich  9 , Salvatore Barberi  9 , Giorgio Ciprandi  10 , Gian Luigi Marseglia  1   2
Affiliations
Review

Omalizumab and allergen immunotherapy for respiratory allergies: A mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

Maria De Filippo et al. Allergol Immunopathol (Madr). .

Abstract

Although currently approved to treat severe asthma and chronic spontaneous urticaria, omalizumab has also been an effective and safe add-on treatment for other allergic diseases. Namely, omalizumab has been proposed to be used as add-on therapy in patients with allergic rhinitis and asthma and undergoing specific allergen immunotherapy (AIT). AIT is the only treatment that modifies the natural history of IgE-mediated diseases. This brief review summarizes the available evidence and controversies on the efficacy and safety of omalizumab combined with specific AIT.

Keywords: Allergen Immunotherapy; Allergic Rhinitis; Asthma; IgE; Omalizumab; Tolerance.

PubMed Disclaimer

References

    1. 1. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol. 2011;127:S1–55. 10.1016/j.jaci.2010.09.034 - DOI
    1. 2. Peanut allergen powder (Palforzia). JAMA. 2020;324(2):192–3. 10.1001/jama.2020.3599 - DOI
    1. 3. Caminiti L, Panasiti I, Landi M, De Filippo M, Olcese R, Ciprandi G, et al. Allergen immunotherapy in atopic dermatitis: Light and shadow in children. Pediatr Allergy Immunol. 2020;31 Suppl 26:46–48. 10.1111/pai.13390 - DOI
    1. 4. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;CD001936.
    1. 5. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010(12):CD002893. 10.1002/14651858.CD002893.pub2 - DOI